Opinion|Videos|November 18, 2026

Patient-Centered Treatment Selection and Shared Decision-Making in Relapsed/Refractory Multiple Myeloma

The panel concludes by discussing patient-centered treatment selection and shared decision-making in relapsed/refractory multiple myeloma.

Episodes in this series

The panel concludes by discussing patient-centered treatment selection and shared decision-making in relapsed/refractory multiple myeloma. Dr. Jing Christine Ye describes using visual tools to help patients understand available treatment options, including clinical trials, while considering efficacy, adverse effects, and logistics. Dr. Paul Richardson emphasizes that the expanding treatment landscape allows clinicians to sequence different modalities based on patients’ individual needs, work and home responsibilities, and quality-of-life priorities. Dr. Douglas Sborov summarizes key considerations associated with CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, emphasizing that treatment selection should reflect each patient’s preferences and circumstances. The panel then shares final takeaways, highlighting the expanding range of therapeutic options, improving safety and outpatient feasibility, and the need for continued research to guide optimal sequencing. Dr. Lee closes by emphasizing the feasibility of outpatient administration of BCMA-directed bispecific antibodies with appropriate infrastructure and supportive-care protocols, underscoring the importance of improving access to these therapies for patients with relapsed/refractory multiple myeloma.


Related to this article